Concepedia

Author

Vicki Goodman

GlaxoSmithKline (United States)

Also Known As

Julie Switzky, V L Goodman, V. Goodman, V. L. Goodman, V.L. Goodman, Vicki Goodman, Vicki L. Goodman

46

Publications

6.8K

Citations

24

H-Index

34

Concepts

All Affiliations

GlaxoSmithKline (United States)Memorial Sloan Kettering Cancer CenterUniversity Hospital Schleswig-HolsteinUniversity of LübeckSir Charles Gairdner Hospital
VG

About

Vicki Goodman is an author at GlaxoSmithKline (United States) specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

14

4.7K

2

Health Sciences

2

2

141

3

Diagnostic Sciences

2

2

141

4

Neurology

2

2

931

5

Molecular Medicine

1

1

111

Vicki Goodman

×

20

Publications

6K

Citations

20

H-Index

YearCitations

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov,

The Lancet

2012

2.9K

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

Georgina V. Long, Uwe Trefzer, Michael A. Davies,

The Lancet Oncology

2012

901

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

Paolo A. Ascierto, David R. Minor, Antoni Ribas,

Journal of Clinical Oncology

2013

422

Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

Edwin P. Rock, Vicki Goodman, Janet Jiang,

The Oncologist

2007

242

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

Michael H. Brave, Vicki Goodman, Edvardas Kaminskas,

Clinical Cancer Research

2008

239

BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i> -Mutant Thyroid Cancer

Gerald S. Falchook, Michael Millward, David S. Hong,

Thyroid

2014

226

Correlation of <i>BRAF</i> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar,

Clinical Cancer Research

2015

201

An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov,

Journal of Clinical Oncology

2013

111

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency

David S. Hong, Luis M. Vence, Gerald S. Falchook,

Clinical Cancer Research

2012

110

Interim results of phase II study BRF113928 of dabrafenib in <i>BRAF</i> V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

David Planchard, Julien Mazières, Gregory J. Riely,

Journal of Clinical Oncology

2013

109

Page 1